Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 16, 2024 11:15 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Receives FDA Approval to Expand NEO100-01™ Phase 2a Clinical Trial to Include Patients with Recurrent Grade III Astrocytoma Brain Tumors Exhibiting IDH1 Mutation

FDA approval reflects positive results from Phase I and preliminary results from Phase IIa study currently underway that demonstrate increased survivability rates in patients with the IDH1...
June 26, 2024 16:39 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Completes $18.5 Million Financing, Advances Phase II Clinical Trials for Enhanced Method of Delivering Novel Therapeutics to the Brain Under FDA Fast-Track Status

New investment and debt conversion by new and existing investors sets company’s post-money valuation at approximately $220 million, up 214% from previous funding round.Financing supports further...
May 15, 2024 11:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Wins California Investment Forum’s Breakthrough Medical Technology Achievement Award

LOS ANGELES, May 15, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, has received the Breakthrough Medical Technology Achievement Award from...
May 09, 2024 17:30 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Invited to Present at California Investment Forum in Anaheim on May 10

LOS ANGELES, May 09, 2024 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage biopharmaceutical company, is proud to be presenting at the 2024 California Investment Forum (CIF),...
June 27, 2023 11:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings Receives FDA Authorization to Proceed with Phase 1/2 Trials of NEO212 for Primary Brain Tumors and for Brain Metastasis in Combination with Standard of Care Therapy

U.S. FDA authorizes NeOnc to initiate Phase 1/2 clinical trials of NEO212.Clinical trials to evaluate NEO212 as a single agent for patients with primary brain tumors or uncontrolled brain...
April 24, 2023 11:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Formalizes Exclusive Global IP Licensing Agreement with USC for Enhanced Method of Delivering Novel Pharma Therapeutics to the Brain

LOS ANGELES, April 24, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has formally secured exclusive worldwide rights from the University...
April 18, 2023 09:15 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Appoints Sidra Medicine CEO and Forbes Top 100 Healthcare Leader, Dr. Iyabo Tinubu-Karch, to Scientific Advisory Board

LOS ANGELES, April 18, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has appointed Dr. Iyabo Tinubu-Karch to its scientific advisory...
April 04, 2023 14:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies CEO, Thomas Chen, MD, Ph.D., Awarded American Health Council’s ‘Best in Medicine’

LOS ANGELES and CHICAGO and LONDON, April 04, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings Inc., a clinical stage medical biotechnology company, announced that its CEO, Thomas Chen, MD,...
March 06, 2023 08:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Engages Anova Enterprises to Pursue Pediatric Brain Tumor Indication and FDA Fast-Track Status for NEO100®

Anova Enterprises, a clinical research organization, to prepare FDA Fast Track and Rare Pediatric Designation application for NEO100® for Pediatric High-Grade Gliomas (pHGGS) brain tumors.AnovaOS™...
February 08, 2023 11:00 ET | Source: NeOnc Technologies Holdings, Inc

NeOnc Technologies Completes $10.0 Million Equity Funding Round

LOS ANGELES, Feb. 08, 2023 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc., a clinical stage medical biotechnology company, has completed a $10.0 million equity funding round at a post-money...